Diurnal Variation of Exogenous Peptides (Endogenous Insulin Jurgita II)
Overview
This is an exploratory trial with two cross-over arms investigating pharmacokinetic profiles of endogenous and exogenous insulin in type 2 diabetes mellitus patients treated with continuous subcutaneous Insulin Aspart infusion and combined with or without intravenous glucose infusion. The order of treatment session will be randomised. Hypotheses: 1. Secretion of endogenous insulin depends on exogenous insulin supply 2. Secretion of endogenous insulin is depends on plasma glucose levels
Full Title of Study: “Interactions Between Exogenous Insulin Aspart, Endogenous Insulin and Plasma Glucose in Type 2 Diabetes Mellitus Patients”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: December 2012
Detailed Description
There are a screening visit and two treatment sessions: Session A: Treatment with Insulin Aspart 1.5 IE/time overnight without intravenous glucose infusion Session B: Treatment with Insulin Aspart 1.5 IE/time overnight with intravenous glucose infusion.
Interventions
- Drug: Insulin Aspart 100 IE/ml
- 1.5 IE/hour/subject/visit. Each vist takes 10 hours
Arms, Groups and Cohorts
- Other: Insulin Aspart without glucose supply
- Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight without intravenous glucose supply
- Other: Insulin Aspart with glucose supply
- Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight combined with intravenous glucose supply
Clinical Trial Outcome Measures
Primary Measures
- Pharmacokinetic profiles of endogenous insulin and Insulin Aspart
- Time Frame: 10 hours
- Pharmacokinetic profiles of endogenous insulin and Insulin Aspart in type 2 diabetes melitus patients treated with continuous subcutaneous Insulin Aspart infusion by insulin pump and combined with or without intravenous supply of glucose
Secondary Measures
- Pharmacodynamic glucose profiles
- Time Frame: 10 hours
- Pharmacodynamic glucose profiles after treatment with Insulin Aspart administred by insulin pump as a continuous subcutaneous infusion .
Participating in This Clinical Trial
Inclusion Criteria
- Subjects with type 2 diabetes mellitus – Insulin-naive patients – HbA1C < 9% – Women and men >= 35 and <= 75 years old – BMI 25-42 kg/m2, both values are included Exclusion Criteria:
- Suspected or known allergy to the trial drug or similar medications – Treatment with hte drugs that after Investigator judgment could potentially interfere with plasma glucose levels – Heart: Unstable angina pectoris, acute myocardial infarction within the last 12 months – Severe uncontrolled hypertension with blood pressure in lying position > 180/110 mmHg – Impaired liver function with liver parameters more than 2 times above the upper normal limit according to the local laboratory – Impaired kidney function with eGFR < 50 ml/min according to the local laboratory – Pregnancy, lactation or desire for pregnancy in the study period and for women in childbearing age without adequate contraception-adequate contraception is: sterilisation, hysterectomy or current use of contraceptive pills, coil, gestagen depot injection, subdermal implantation, hormonal vaginal ring and transdermal depot patch.
Gender Eligibility: All
Minimum Age: 35 Years
Maximum Age: 75 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Aarhus University Hospital
- Provider of Information About this Clinical Study
- Principal Investigator: Jurgita Janukonyte, Medical doctor – Aarhus University Hospital
- Overall Official(s)
- Jurgita Janukonyte, MD, Principal Investigator, University of Aarhus
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.